Cancer genomes are heterogeneous and complex, and distinguishing oncogenic drivers from bystander lesions that occur as a result of genomic instability remains a major challenge. In contrast to some hematopoietic malignancies, for which molecular therapies can induce long-lasting tumor remissions, clinical experiences over the past couple of years have revealed that in the most common types of solid tumors, acquired therapy resistance against molecular therapies is inevitable 1-3 . Hepatocellular carcinoma can be seen as a prototypical therapy-resistant tumor, and it represents a major health problem, causing more than 700,000 deaths annually worldwide 4 . HCC shows intrinsic resistance to cytotoxics 5, 6 , and although the multikinase inhibitor sorafenib was recently approved as the first systemic treatment for patients with advanced HCC, the survival advantage conferred to these patients from sorafenib therapy averages only 2.8 months 7 . Sorafenib targets wild-type Raf1, mutant and wild-type Braf, and vascular endothelial growth factor receptors 2 and 3 (Vegfr2, Vegfr3) 8 , and it is currently unclear how sorafenib resistance occurs at the molecular level. Taking advantage of a recently developed system for transposonmediated in vivo delivery of miRNA-based short hairpin RNAs (shRNAs) 9,10 , we developed a platform that can be used to conduct negative-selection shRNA screens directly in mouse liver carcinomas in vivo. A pooled shRNA screen conducted to identify target genes whose inhibition increases the therapeutic efficacy of sorafenib identified Mapk14-dependent activation of Mek-Erk and Atf2 signaling as a key mechanism of sorafenib resistance in mouse and human liver cancer. Combined sorafenib treatment and Mapk14 inhibition decreased proliferation of HCCs in vivo and significantly prolonged survival of tumor-bearing mice. Our results establish a tractable system for functional and direct in vivo identification of treatment-response modifiers in HCC and suggest that Mapk14 inhibition is a promising strategy to increase the therapeutic efficacy of sorafenib.
Cancer genomes are heterogeneous and complex, and distinguishing oncogenic drivers from bystander lesions that occur as a result of genomic instability remains a major challenge. In contrast to some hematopoietic malignancies, for which molecular therapies can induce long-lasting tumor remissions, clinical experiences over the past couple of years have revealed that in the most common types of solid tumors, acquired therapy resistance against molecular therapies is inevitable [1] [2] [3] . Hepatocellular carcinoma can be seen as a prototypical therapy-resistant tumor, and it represents a major health problem, causing more than 700,000 deaths annually worldwide 4 . HCC shows intrinsic resistance to cytotoxics 5, 6 , and although the multikinase inhibitor sorafenib was recently approved as the first systemic treatment for patients with advanced HCC, the survival advantage conferred to these patients from sorafenib therapy averages only 2.8 months 7 . Sorafenib targets wild-type Raf1, mutant and wild-type Braf, and vascular endothelial growth factor receptors 2 and 3 (Vegfr2, Vegfr3) 8 , and it is currently unclear how sorafenib resistance occurs at the molecular level.
Taking advantage of a recently developed system for transposonmediated in vivo delivery of miRNA-based short hairpin RNAs (shRNAs) 9,10 , we developed a platform that can be used to conduct negative-selection shRNA screens directly in mouse liver carcinomas in vivo. A pooled shRNA screen conducted to identify target genes whose inhibition increases the therapeutic efficacy of sorafenib identified Mapk14-dependent activation of Mek-Erk and Atf2 signaling as a key mechanism of sorafenib resistance in mouse and human liver cancer. Combined sorafenib treatment and Mapk14 inhibition decreased proliferation of HCCs in vivo and significantly prolonged survival of tumor-bearing mice. Our results establish a tractable system for functional and direct in vivo identification of treatment-response modifiers in HCC and suggest that Mapk14 inhibition is a promising strategy to increase the therapeutic efficacy of sorafenib.
RESULTS

Generation of therapy-resistant mouse HCCs using a transposon-based mouse model
To model hepatocellular carcinoma in mice, we took advantage of a well-established mouse model in which transposable elements are stably delivered into the liver via hydrodynamic tail-vein injection 10, 11 ( Supplementary Fig. 1 ). Stable delivery of oncogenic Nras G12V (using the pCaN vector; Fig. 1a ) into the livers of p19 Arf -deficient mice triggers the growth of aggressive multifocal HCCs, whereas, as also reported recently 10 , no tumor growth is observed when Nras G12V was delivered into C57BL/6 wild-type livers (Fig. 1b) . To facilitate imaging and quantification of HCCs, we generated a transposon vector for coexpression of Nras G12V and green fluorescent protein (GFP) (pCaNIG; Fig. 1a ) and found that GFP expression did not affect either the tumor burden or the survival of tumor-bearing mice (Fig. 1c,d) .
We recently showed that miRNA-based shRNAs (hereafter referred to as shRNAs) can be expressed efficiently from transposons to generate stable knockdown phenotypes in mouse livers 9 . To explore whether oncogene-encoding transposable elements can be used to engineer mouse HCCs with stable knockdown of target genes, we generated transposons (pCaNIG-shRNA; Fig. 1a ) encoding Nras G12V , GFP, and either different noncoding shRNAs (shNC) or a previously described shRNA targeting Cdkn2a that encodes the tumor suppressors p16 Ink4A and p19 Arf (ref. 12) (shp16 Ink4A /p19 Arf ). Transposon vectors were stably delivered into the livers of p19 Arfdeficient mice, where they triggered HCCs with latency comparable to those of vectors without shRNA expression (Fig. 1c,d ).
Tumors stably expressing pCaNIG-shp16 Ink4A /p19 Arf showed efficient intratumoral p16 Ink4A knockdown; however, p16 Ink4A silencing did not further accelerate tumor growth (Fig. 1d,e) . Histopathological analyses revealed that engineered mouse HCCs resemble moderately to poorly differentiated human HCC in their histopathology (Fig. 1c) . In summary, these data show that multifocal HCCs can be triggered by direct and stable intrahepatic delivery of transposons encoding oncogenes, marker genes and shRNAs and that intratumoral shRNA expression results in high knockdown efficiency.
Currently more than 90% of all new oncology drugs entering early clinical testing fail in later phases of clinical development 13, 14 , indicating that higher bars are needed in preclinical drug testing. To assess whether our transposon-based mouse model of liver cancer recapitulates the therapy resistance of human HCC, we treated mice harboring Nras G12V -driven HCCs with sorafenib. Strikingly, sorafenib barely reduced intrahepatic tumor burden (Fig. 1f) and resulted in a very limited, although statistically significant, survival advantage averaging 8 d (P = 0.0239) (Fig. 1g) Arf -deficient mice after delivery of pCaN (n = 6), pCaNIG (n = 6), pCaNIG-shNC (n = 7) and pCaNIG-shp16 Ink4A /p19 Arf (n = 7) transposons (no statistical significant difference between the different groups could be found by log-rank test).
(e) In vivo knockdown test of transposon-encoded shRNAs by p16 Ink4A western blot analysis from tumors triggered by pCaNIG-shp16 Ink4A /p19 Arf or pCaNIG-shNC delivery into p19 Arf -deficient mice (n = 3 for each condition). (f) Intrahepatic tumor burden of p19 Arf -deficient mice 5 weeks after injection of pCaNIG and treatment with sorafenib (100 mg/kg, n = 5) or carrier (n = 6) (representative photographs and GFP images; scale bars, 1 cm). (g) Survival analyses (Kaplan-Meier format) of p19 Arf -deficient mice after injection of pCaNIG and treatment with sorafenib (n = 6) or carrier (n = 7) (treatment was started 1 week after injection; statistical significance was calculated using a log-rank test). Direct in vivo RNAi screening for sorafenib sensitizer genes We reasoned that the established mouse model would be ideally suited for direct in vivo negative-selection RNA interference (RNAi) screens to identify gene products that mediate resistance to sorafenib. To determine the complexity of shRNA pools that could be screened in our model, we stably delivered two different noncoding shRNAs (shNC1 and shNC2) into mouse livers (pCaNIG vector; Fig. 1a ) at different ratios. After 4 weeks, we harvested genomic DNA from tumorbearing livers and used it for PCR amplification of shRNA cassettes (Fig. 2a) . We performed deep sequencing of PCR products to quantify the abundance of each shRNA and calculated the ratios between them. Given that both shRNAs could be safely recovered from tumor-bearing livers, even when shRNAs were injected at a 1:500 ratio (Fig. 2b) , we reasoned that pools with a complexity of up to 500 shRNAs could be used for shRNA screening in our mouse model. Oncogenic drivers of human tumors are often found in focal chromosomal amplifications and might also be involved in mediating therapy resistance. We therefore compiled a focused shRNA library targeting genes located within focal genomic amplifications of approximately 100 human HCCs 15 (Amplicon set, on average 3.4 shRNAs per gene) (Fig. 2c) .
We generated pCaNIG-shRNA transposons encoding the amplicon shRNA set and delivered them into p19 Arf -deficient mice. We treated half of the mice with sorafenib and the other half with carrier (Fig. 2d) . After 5 weeks, we extracted genomic DNA from tumorbearing livers of both groups and determined the abundance of each shRNA in each liver by deep sequencing (Fig. 2d) . We calculated average values for the total number of sequence reads to determine the proportion of each shRNA within the whole population, and later used these data to calculate the fold enrichment or depletion of each shRNA between sorafenib-and carrier-treated mice (Fig. 2e,f and Supplementary Table 1 ). As expected, the majority of shRNAs had no impact on sorafenib sensitivity, and therefore their frequencies did not differ significantly between sorafenib-and carrier-treated mice (Fig. 2e,f) . However, 28 shRNAs were enriched more than 10-fold, and 19 shRNAs were depleted more than 10-fold, in sorafenib-compared to carrier-treated mice (Fig. 2f, Supplementary  Table 1 ). For follow-up studies, only gene targets that were represented by two independent shRNAs that each showed at least 10-fold depletion were included. Only one candidate gene, the mitogenactivated protein kinase 14 (Mapk14 or p38α) gene, fulfilled these criteria, with shMapk14.1095 being depleted 138-fold and shMapk14.2590 being depleted 324-fold.
shRNA-mediated Mapk14 knockdown sensitizes liver carcinomas for sorafenib Mapk14, a member of the MAP kinase family, can be activated by various environmental stresses and proinflammatory cytokines. It represents a dual-function protein, as it can inhibit cell cycle progression or even induce cellular senescence or apoptosis in normal cells but increase proliferation in cancer cells 16, 17 .
Both Mapk14 shRNAs identified in the screen yielded good knockdown efficiencies (Supplementary Fig. 2 ). We tested them individually using the experimental setup employed in the screen by hydrodynamically injecting p19 Arf -deficient mice with pCaNIGshMapk14.1095, pCaNIG-shMapk14.2590 or pCaNIG-shNC and treating them with sorafenib or carrier (Fig. 3a) . Stable knockdown of Mapk14 per se had no impact on intrahepatic tumor burden or overall mouse survival (Fig. 3b,c) , but intratumoral knockdown of Mapk14 sensitized the mice to sorafenib treatment and resulted in lower tumor burden and significantly longer survival than was observed for mice bearing shNC-expressing tumors treated with sorafenib (P < 0.05) (Fig. 3b,d ). TdT-mediated dUTP-biotin nick end-labeling (TUNEL) showed no greater apoptosis of sorafenib-treated tumors as a result of Mapk14 knockdown ( Fig. 3e and Supplementary Fig. 3a) ; however, Ki67 staining revealed markedly lower proliferation of sorafenibtreated shMapk14-expressing tumors compared to shNC-expressing tumors ( Fig. 3f and Supplementary Fig. 3b ), thus suggesting that The representation of each shRNA after sorafenib treatment (n = 9) was compared to its representation after treatment with carrier alone (n = 9).
(f) Overview of shRNAs that showed at least 10-fold depletion in sorafenib-treated mice compared to carrier-treated mice. Plotted are the fold changes of shRNA abundance in the sorafenib-treated group compared to carrier-treated group. Top-scoring shRNAs targeting Mapk14 are marked in red.
npg sorafenib sensitization through Mapk14 inhibition is due mainly to reduced tumor cell proliferation.
To explore whether the combined use of sorafenib and Mapk14 inhibition shows efficacy against advanced HCC, we next took advantage of a mouse model enabling conditional RNA interference in progressed HCC. We injected mouse Nras G12V ; p19 Arf -deficient HCC cells stably expressing doxycycline-responsive Mapk14 or control shRNAs (pTtGMP and rtTA3 vectors; Fig. 3g ) under the liver capsules of immunocompetent C57BL/6 mice, where orthotopic HCCs developed. Doxycycline was administered 1 week after cell injection, and treatment with sorafenib or carrier was started simultaneously (Fig. 3g) . Strikingly, we found marked therapeutic efficacy even in this intervention treatment setup of already advanced HCCs. Mice with induced shMapk14 (+doxycycline) lived significantly longer than mice without Mapk14 knockdown under sorafenib treatment (P = 0.033 shNC versus shMapk14, +doxycycline) and also showed a strongly reduced tumor burden (Fig. 3h,i) . Notably, tumors that arose in doxycyclinetreated shMapk14 mice showed weak to no GFP expression (Fig. 3i) , which, as GFP and shRNA expression are linked in our system, suggests strong selection against shRNA expression. Therefore, the data we obtained may even underestimate the real therapeutic efficacy of combined sorafenib and Mapk14 inhibition treatment.
Pharmacological inhibition of Mapk14 increases therapeutic efficacy of sorafenib
We next set out to explore whether our genetic findings could be translated into a pharmacological combination therapy. Several Mapk14 inhibitors are available 18, 19 , and we confirmed efficient Fig. 4) .
To test the efficacy of pharmacological combination therapy of sorafenib and Mapk14 inhibition, we next treated mice with sorafenib and BIRB796 after orthotopic and autochthonous HCCs had been triggered by oncogenic Nras G12V in the livers of p19 Arf -deficient mice. We treated tumor-bearing mice with either carrier, sorafenib or BIRB796 alone or in combinations, again starting 1 week after induction of tumor growth. Strikingly, mice receiving BIRB796 combined with sorafenib showed markedly lower intrahepatic tumor burden and significantly longer survival than mice given monotherapy (Fig. 4a,b) .
To confirm our results with a second, independent Mapk14 inhibitor, we incubated cells from an Nras G12V -driven mouse liver tumor with SB202190. In line with our previous data, we found only a subtle reduction in colony formation upon sorafenib or SB202190 monotherapy; however, colony formation was strongly suppressed when sorafenib and SB202190 were combined (Fig. 4c) .
We next extended our studies to mouse liver cancer cells of other genotypes to address whether combined sorafenib and Mapk14 inhibitor therapy is applicable to liver carcinomas with different driving oncogenes. Strikingly, we observed similar activity of our combination therapy both in Nras G12V -driven liver carcinomas, which additionally harbor a constitutively active form of Akt-1 (Nras G12V ; Akt-1; p19 Arfdeficient cells) (Fig. 4d) , and in tumor cells outgrown from c-myc/ Akt-1-driven liver carcinomas (Fig. 4e) . We also found pronounced therapeutic efficacy when we combined sorafenib and different Mapk14 inhibitors to treat several different human HCC cells, namely Hep3B, Huh7 and PLC/PRF/5 cells (Fig. 4f-h and Supplementary  Fig. 5 ). Taken together, our data suggest that sorafenib and Mapk14 inhibition therapy shows robust therapeutic activity in mouse and human liver carcinomas of different genetic backgrounds.
Second-generation Mapk14 inhibitors combine high target selectivity and therapeutic efficacy without adverse drug effects in vivo To set the basis for a rapid translation of our results into clinical trials, we next explored the therapeutic efficacy of highly selective and potent second-generation Mapk14 inhibitors (skepinone-L and PH-797804), which, in contrast to first-generation Mapk14 inhibitors 20 , show no significant side effects when used preclinically and in clinical trials [21] [22] [23] [24] . Although skepinone-L is still undergoing preclinical testing, PH-797804 is currently in a phase 2 clinical trial for the treatment of patients with chronic obstructive lung disease (COPD) and rheumatoid arthritis, and interim analyses have yielded no signs of significant adverse side effects 24 . Both second-generation Mapk14 inhibitors showed pronounced therapeutic efficacy when combined with sorafenib for the treatment of mouse and human HCCs in vitro (Fig. 5a,b and Supplementary Fig. 6a ) and in vivo (Fig. 5c,d) , and skepinone-L by trend showed superior efficacy (Fig. 5a-d and Supplementary Fig. 6a) .
As an indicator of potential adverse drug effects, we followed up weight development of mice treated with sorafenib + skepinone-L combination therapy, but we did not detect any decrease in body weight over time (Fig. 5e) . As liver carcinomas mostly arise in chronically damaged livers with impaired function and regenerative capacity, it is of utmost importance that antitumorigenic treatments of HCC do not negatively impact the regenerative capacity of hepatocytes. To address whether our combination therapy affects liver regeneration, we performed two-third hepatectomies on mice that were on combined sorafenib + Mapk14 blockade treatment (Fig. 5f) . Importantly, mice on combination therapy showed normal gain of body weight G12V and indicated treatment, as described in a (carrier, n = 4; BIRB796, n = 7; sorafenib, n = 9; sorafenib + BIRB796, n = 10; statistical significance was calculated using a log-rank test). and even slightly better liver regeneration upon partial hepatectomy compared to carrier-treated mice (Fig. 5g,h and Supplementary  Fig. 6b ). These data show that a combinatorial treatment with sorafenib and second-generation Mapk14 inhibitors is well tolerated and has no negative impact on liver regeneration.
Mapk14 inhibition attenuates Mek-Erk signaling in sorafenib-treated HCC
To gain mechanistic insights into how Mapk14 inhibition sensitizes HCCs to sorafenib, we subjected shMapk14-expressing and shNC-expressing mouse HCC cells to sorafenib treatment and conducted mRNA expression profiling and Ingenuity pathway analyses ( Fig. 6a and Supplementary Fig. 7 ). These analyses revealed significantly downregulated Mapk14 (p38α)-dependent signaling in shMapk14-expressing cells compared to shNC-expressing cells, thus confirming the validity of our approach (P < 0.05) (Fig. 6b) . In line with sorafenib's high affinity for Raf proteins 8 , we also found a much lower number of Raf1-, Mek-and Erk-dependent signaling events in shNC-expressing cells treated with sorafenib than in those treated with DMSO. Unexpectedly, however, we also found that Raf1-, Mek-and Erk-dependent signaling was further attenuated upon shRNA-mediated silencing of Mapk14 (Fig. 6b) , suggesting that there is cross-talk between Mapk14 signaling and the RafMek-Erk cascade in liver cancer cells. Western blot analyses of sorafenib-treated shNC or shMapk14 cells confirmed that Mapk14 silencing resulted in a marked reduction of phospho-(p-) Mek1 and p-Erk1/2 using phospho-specific antibodies, which was accompanied by reduced cell proliferation, as indicated by strongly decreased expression of cyclin A (Fig. 6c) .
Mek-Erk signaling is reported to be upregulated in more than 50% of all human HCCs 25,26 and represents a major oncogenic driver in liver cancer 25, 27 . Our data thus far suggested that sorafenibmediated suppression of the Mek-Erk cascade (via Raf inhibition) is not fully efficient, and that suppression can be further enhanced through Mapk14 silencing. Given the important role of Mek-Erk signaling in controlling the proliferation of liver cancer cells, we hypothesized that Mapk14-dependent cross-signaling into the MekErk cascade might be involved in mediating sorafenib resistance, as upregulation of Mapk14 signaling would allow Mek-Erk signaling to be maintained even when Raf was blocked by sorafenib. To address this hypothesis experimentally, we subjected mouse and human liver cancer cells to short-and long-term sorafenib treatment and analyzed p-Mapk14 as well as p-Mek and p-Erk levels. Indeed, long-term exposure of mouse or human hepatoma cells to sorafenib resulted in strong induction of p-Mapk14 accompanied by a marked increase in p-Mek and p-Erk (Fig. 6d and Supplementary Fig. 8a ). HCC cells with p-Mapk14 induction and reactivated Mek-Erk signaling were no longer responsive to sorafenib treatment and regained high proliferation rates (Supplementary Fig. 8b) . Detailed time-course analyses in panels of mouse and human hepatoma cells and Nras G12V -driven tumors in vivo revealed that the timing of p-Mapk14 induction under sorafenib treatment varied between different types of HCC (Supplementary Fig. 9 ). Furthermore, expression profiling and Ingenuity pathway analyses suggested that Tgfbr1-mediated signaling npg may be involved in Mapk14 induction and development of sorafenib resistance (Supplementary Fig. 10 ).
In further support of the hypothesis that induction of Mapk14 signaling may be a key mechanism of resistance to sorafenib treatment, we found marked clonal expression of p-Mapk14 in HCC tissue obtained from biopsies of two patients receiving sorafenib therapy (Supplementary Fig. 11a ). For ethical reasons tumor biopsies are not routinely taken from patients undergoing sorafenib therapy, and we therefore also aimed to assess whether the pretherapeutic Mapk14 activation level can predict the outcome of sorafenib therapy in patients with HCC. Interestingly, high pretherapeutic staining of both p-Mapk14 and its downstream target p-Atf2 correlated with a shorter survival on sorafenib therapy (Fig. 6e,f and Supplementary  Fig. 11b,c) , whereas p-Atf2 staining more strongly predicted response to sorafenib therapy than p-Mapk14 (P < 0.001). This appears to be an example of the common phenomenon of signal amplification of downstream factors in a signaling pathway and highlights p-Atf2 as a robust biomarker for predicting response to sorafenib therapy. In further support of the idea that pretherapeutic differences in Mapk14 activity exist between sorafenib-sensitive and sorafenib-resistant tumors, studies on different mouse and human hepatoma cells revealed that pretherapeutic Mapk14 activation status correlated with response to sorafenib therapy (Supplementary Fig. 12) .
Because mRNA expression profiling and western blot analyses also revealed pronounced downregulation of Atf2-dependent signaling as a result of Mapk14 silencing (Fig. 6b,c) , we sought to explore whether Atf2 reduction upon Mapk14 silencing per se contributes to sorafenib sensitization or whether the increased therapeutic efficacy of sorafenib is solely due to reduced Mek-Erk signaling in Mapk14-silenced cells. We generated mouse liver cancer cells with stable knockdown of Atf2 (Supplementary Fig. 13a ), subjected them to sorafenib or DMSO treatment and quantified cell proliferation ( Fig. 6g and Supplementary Fig. 13b) . Although in the absence of sorafenib Atf2 knockdown reduced cell proliferation only slightly, the combination of sorafenib treatment and stable Atf2 suppression reduced cell proliferation below the level seen with sorafenib therapy alone. Therefore, our data suggest that decreased Atf2-dependent transcription may contribute to sorafenib sensitization upon Mapk14 blockade.
Recent reports suggest that, in addition to inducing Mek-Erk activation, Raf proteins can signal to other downstream targets in cancer cells 28, 29 . To explore the significance of such additional Raf downstream targets in liver cancer, we compared the therapeutic efficacies of combinations comprising Raf inhibition (vemurafenib) plus Mapk14 blockade or Mek1/2 blockade (PD325901) plus Mapk14 blockade. Strikingly, whereas combined vemurafenib and Mapk14 blockade phenocopied the results obtained with sorafenib and Mapk14 blockade (Fig. 6h) , blockade of both Mek and Mapk14 produced only a marginal antiproliferative effect (Fig. 6i) . However, as expected, full therapeutic efficacy was observed when Raf inhibition, Mek blockade and Mapk14 inhibition were combined (Fig. 6i) . Likewise, full therapeutic efficacy was observed when liver cancer cells with shRNA-mediated Atf2 knockdown were treated with a combination of Mek and Raf inhibitors, whereas combined Raf and npg Mek inhibition without additional Atf2 silencing did not yield the full antiproliferative effect (Fig. 6i) . In summary, these data suggest a working model whereby full therapeutic efficacy of sorafenib and Mapk14 blockade therapy relies on three modules: (i) Mek-Erk inhibition, (ii) inhibition of non-Mek-Erk downstream targets of Raf and (iii) Atf2 inhibition (Fig. 6j) .
Importantly, particularly in regard to clinical trials to test sorafenib and Mapk14 inhibition in patients with HCC, we found that sorafenib plus Mapk14 inhibition is effective against liver cancer cells that have developed sorafenib resistance (Supplementary Fig. 14) . Accordingly, clinical trials testing sorafenib and Mapk14 inhibition can be designed so that patients can first undergo standard therapy (sorafenib) and then participate in a trial that explores the combination treatment.
DISCUSSION
Recent work has shown that RNAi-based functional genetic screening is a powerful approach to characterize molecular mechanisms of therapy resistance [30] [31] [32] [33] . However, such screens were mostly conducted in vitro and therefore cannot survey gene activities that are related to the complex three-dimensional tumor architecture and microenvironment.
Here we present a unique platform that for the first time (to our knowledge) makes it possible to conduct shRNA drop-out screens in tumors directly in vivo-that is, in a setting where the tumor cells to be screened have never been removed from their natural threedimensional environment. We reasoned that our system would therefore be ideally suited to dissect molecular mechanisms of therapy resistance in liver cancer and to pinpoint new target genes whose inhibition can increase the therapeutic efficacy of the multikinase inhibitor sorafenib, the only systemic treatment for HCC currently approved by the US Food and Drug Administration. Our screening platform turned out to be highly robust and functionally identified Mapk14 as a target whose inhibition strongly sensitizes tumors to sorafenib therapy. Against the background of its promiscuous cellular effects, it is unlikely that Mapk14 would have been selected as a candidate gene for sorafenib sensitization based on hypothesis-driven approaches. Therefore, our data emphasize the power of unbiased functional genetic screens to identify new gene targets in different biological systems.
Our mouse model is highly flexible and can also be used for screening other focused shRNA libraries, either as straight lethality screens to directly pinpoint new vulnerabilities or, in conjunction with other targeted therapies or cytotoxics, as a means to identify new drug sensitizer or resistance genes. Notably, as our data show that pools of up to 500 shRNAs can be screened per mouse with our approach, it is even conceivable to conduct genome-scale screens, assuming that a genome-scale library is split into sets of maximum 500 shRNAs and screened in a sufficient number of mice. We believe that the results we present herein have high and direct translational potential, as combination therapies of sorafenib and second-generation Mapk14 inhibitors should be practicable for patients with HCC without imposing significant side effects. Although first-generation p38 inhibitors lacked specificity for Mapk14 and therefore exerted toxicity in clinical trials 20 , highly specific and efficient Mapk14 inhibitors are now available that show no or very benign toxicity profiles 21, 24 . For example, PH-797804 and ARRY-371797 have completed phase 1 or phase 2 clinical trials for different non-cancer-related diseases (for example, NCT00729209, NCT01366014, NCT00383188 and NCT00559910). The lack of toxicity, especially liver toxicity, is of particular importance for the treatment of patients with liver cancer as the majority of hepatocellular carcinomas arise in cirrhotic livers with impaired liver function. Regarding the design of clinical trials to test the efficacy of Mapk14 inhibition in combination with sorafenib in human HCC, it is noteworthy that Mapk14 blockade can restore sorafenib sensitivity in tumors that have become resistant upon longterm sorafenib treatment. This finding might facilitate the initiation of clinical trials as patients could first undergo standard therapy (sorafenib) and then participate in a trial exploring the combinatorial use of sorafenib and Mapk14 blockade. As our data suggest the Mapk14 downstream factor Atf2 as a robust biomarker to predict poor responses toward sorafenib therapy, it should be explored whether patients with higher pretherapeutic p-Atf2 signals are candidates to start combination therapy directly.
METHODS
Methods and any associated references are available in the online version of the paper. 
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